
@ExelixisInc recently announced that the FDA has accepted a new drug application for a potential treatment combo
If approved, this combo could represent another potential treatment option for patients living w/ non-msi high mcrc
➡️ Read more in their PR: ir.exelixis.com/news-releases/…




English




















